Literature DB >> 12974091

[Treatment of ovarian cancer cell line Skov3 with HSV-tk/GCV under the control of human telomerase reverse transcriptase gene promoter].

Yue Song1, Bei-hua Kong, Pei-shu Liu, Dao-xin Ma, Xun Qu, Sen Jiang.   

Abstract

OBJECTIVE: To investigate the in vitro effect of HSV-tk/GCV using a hTERT promoter-driven vector system on Skov3 ovarian cancer cells.
METHODS: An expression vector (pBTdel-279-tk) containing tk gene under the hTERT promoter was constructed by molecular biological methods, and then was transfected into Skov3 ovarian cancer cells, normal ovarian epithelial cells (NOEC) and human embryonic lung fibroblast by cationic liposome. Following the transfection with tk, GCV was added, and MTT and flow cytometry methods were applied to investigate its antitumor effect. RT-PCR was used to detect the tk gene in ovarian cancer cells and normal cells after the transfection of pcDNA3-tk or pBTdel-279-tk.
RESULTS: pBTdel-279-tk/GCV system induced apoptosis in hTERT-positive ovarian cancer cells, but not in hTERT-negative normal ovarian epithelial cells and fibroblasts. The hTERT promoter system was almost as efficient in inducing cancer cell death as the CMV promoter. tk gene was expressed in Skov3 cells and NOEC after pcDNA3-tk transfection, while positive was only in ovarian cancer cells after pBTdel-279-tk transfection.
CONCLUSION: The telomerasespecific transfer of the tk gene under the hTERT promoter is a novel targeting approach for the treatment of ovarian cancer and may lead to an effective and specific gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974091

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  1 in total

1.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.